JPM 2026

Fierce Pharma

Astellas CEO resists 'rescue BD' as Xtandi patent cliff nears

With Xtandi set to lose U.S. patent protection next year, Astellas’ CEO fielded questions this week about his company’s BD strategy ahead of the loss.

Angus Liu Jan 15, 2026 10:42am

Boston Scientific to snap up Penumbra in deal valued at $14.5B

Jan 15, 2026 8:12am

JPM26: All of the meetings, none of the megadeals

Jan 15, 2026 4:30am

JPM26, Day 3: Hundreds attend Biotech CEO Sisterhood meetup

Jan 14, 2026 3:34pm

Union Square in San Francisco during JPM 2026

JPM26: Sanofi looks ahead to lingering US policy hurdles

Jan 14, 2026 2:28pm

JPM: Illumina working with China on export troubles, CEO says

Jan 14, 2026 8:25am